Homepage

Let’s work together to speed up the discovery of new drugs by combining continuous flow chemistry, automation and artificial intelligence
ABOUT OUR TECHNOLOGY

Continuous flow chemistry

our_technology

At Fluidichem, we are revolutionising drug development with cutting-edge technology. Our innovative approach combines artificial intelligence (AI) with continuous flow chemistry to transform the synthesis of molecule libraries. This groundbreaking solution ensures rapid and efficient drug development across all phases beyond discovery.

At the heart of our work lies our high-throughput automated synthesis robot, based on continuous flow chemistry and leveraging AI support to guarantee speed, efficiency and adaptability.

ABOUT US

Our CEO

Eric Wimmer’s unwavering passion for science led him to specialise in organic chemistry, culminating in a PhD from the University of Strasbourg. However, his academic journey took a transformative turn during a post-doctoral stint at the University of Nantes under the guidance of Prof. Felpin. There, Eric immersed himself in the realms of continuous flow chemistry and automation, venturing beyond traditional academic boundaries into the fields of programming and automation.

The synergy of these diverse disciplines struck Eric with a realization — the amalgamation of these technologies held extraordinary promises for shaping the future of chemistry. The groundbreaking research conducted at the University of Nantes, under Eric’s contributions, not only resulted in significant publications but also earned him distinctions, notably the GdR Synth Flux prize from a community of French-speaking chemists specializing in continuous flow chemistry.

The expertise Eric gained during his post-doctoral tenure, ranging from flow chemistry to programming, online analysis, and automation, became the cornerstone of Fluidichem’s subsequent approach and success story.

Eager to refine his skills further in continuous flow chemistry, Eric sought additional experience through a post-doctoral position at Servier. This opportunity provided Eric with invaluable insights into the challenges and intricacies of the pharmaceutical industry. Armed with this comprehensive understanding, he meticulously fine-tuned his vision, paving the way for the establishment of Fluidichem.

Today, Eric’s journey stands as a testament to the symbiosis of academic rigor, interdisciplinary exploration, and entrepreneurial vision, reflecting his commitment to advancing the frontiers of chemistry and technology for the benefit of the chemical and pharmaceutical industry.